AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04682405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided by study
Trial: NCT06021145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
Trial: NCT05325515
Drug: Effervescent and buffered alendronate
RxNorm normalized name: alendronate Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent and buffered alendronate 70mg weekly
Trial: NCT06310538
Drug: Hongjin Xiaojie Capsules
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
Trial: NCT05032560
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ABX464 ABX464 is a new anti-inflammatory drug
Trial: NCT05032560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Matching Placebo placebo matching with ABX464
Trial: NCT06296966
Drug: VSJ-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT06296966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT04840615
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
Trial: NCT00000950
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06278090
Drug: Ursodeoxycholic Acid Only Product
RxNorm normalized name: Ursodeoxycholic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months
Trial: NCT04653493
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04231643
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one-time oral administration of placebo
Trial: NCT06203080
Drug: ancetate gel
RxNorm normalized name: acetic acid Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
Trial: NCT05477810
Drug: Treatment A (investigational drug) followed by Treatment B (reference drug)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Trial: NCT05477810
Drug: Treatment B (reference drug) followed by Treatment A (investigational drug)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Trial: NCT05895747
Drug: Low Dose Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate 5g PO qday
Trial: NCT05895747
Drug: High Dose Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate 10g PO qday
Trial: NCT05895747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Trial: NCT05320120
Drug: 0.9% saline solution nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution nasal spray
Trial: NCT06307288
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
Trial: NCT05196945
Drug: Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
Trial: NCT04603690
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will receive standard of care as per the hospital guidelines
Trial: NCT05745363
Drug: AL2846 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 is a multi-target tyrosine kinase inhibitor
Trial: NCT05333107
Drug: NNC0385-0434 G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Trial: NCT05333107
Drug: NNC0385-0434 F
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Trial: NCT05333107
Drug: NNC0385-0434 B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Trial: NCT06468254
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.
Trial: NCT05954806
Drug: Antivenom Snakes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
Trial: NCT06153329
Drug: THDB0206 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
Trial: NCT06153329
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
Trial: NCT04786990
Drug: SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine extended-release capsule
Trial: NCT04847947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
Trial: NCT04392999
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of corticosteroid into the cervical facet joints.
Trial: NCT05084963
Drug: IRL201104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilised powder for reconstitution for IV dosing
Trial: NCT05084963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for IRL201104
Trial: NCT05805904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06441591
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
Trial: NCT05376085
Drug: DA-5215-R Tab
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 1 tablet of DA-5215-R Tab with 150mL water
Trial: NCT04758780
Drug: 89Zr-TLX250 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretherapeutic 89Zr-TLX250 PET/CT
Trial: NCT05358379
Drug: CYC140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Trial: NCT00845689
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9 %
Trial: NCT00845689
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion of adenosine 0, 2 %
Trial: NCT00845689
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion of adenosine 0,2 %
Trial: NCT06258356
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline (compared to Remimazolam)
Trial: NCT05163691
Drug: 5 Methoxy N,N Dimethyltryptamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH001 administered via inhalation
Trial: NCT05163691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH001 Placebo administered via inhalation
Trial: NCT00001006
Drug: AS-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06077786
Drug: Placebo to Lu AG06474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT06077786
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule
Trial: NCT06077786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT05323981
Drug: HS627(210mg/7ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of 420mg HS627
Trial: NCT05323981
Drug: HS627(420mg/14ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of 420mg HS627
Trial: NCT05845723
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
Trial: NCT05192369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet) dosed with water
Trial: NCT05365178
Drug: TQB3616 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
Trial: NCT05365178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a placebo
Trial: NCT05292846
Drug: Direct-acting oral anticoagulation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban Dabigatran Edoxaban Rivaroxaban
Trial: NCT05240456
Drug: Beta3-Agonists, Adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
Trial: NCT05240456
Drug: Anticholinergic drug, Solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
Trial: NCT05392959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for dapagliflozin film-coated tablets 10 mg
Trial: NCT05079529
Drug: β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
Trial: NCT05079529
Drug: Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Takes placebo capsule 3 times daily for 90 days
Trial: NCT06446557
Drug: standard management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
Trial: NCT00625157
Drug: ASF 1096 0.5 % cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00625157
Drug: ASF 1096 placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06018116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06258746
Drug: [14C]HSK31679
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
Trial: NCT05654831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.
Trial: NCT05654831
Drug: ECC5004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECC5004 will be administered as oral tablet(s) during each dosing day.
Trial: NCT00000938
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05841095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution (0.9% NaCl)
Trial: NCT05404490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Trial: NCT05218616
Drug: Aviga, capsules 50 mg / Sutent®, capsules 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
Trial: NCT05218616
Drug: Sutent®, capsules 50 mg / Aviga, capsules 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
Trial: NCT04540094
Drug: Balanced crystalloid solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study.
Trial: NCT05661591
Drug: SHR2554 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 Tablets+ Fluconazole Capsules
Trial: NCT06628622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05493163
Drug: Thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
Trial: NCT05493163
Drug: Standard anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulation therapy of acute pulmonary embolism.
Trial: NCT04818398
Drug: DS-6016a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
Trial: NCT04818398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
Trial: NCT04298151
Drug: Zirconomer Improved
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
Trial: NCT04298151
Drug: Ketac Molar quick Aplicap
RxNorm normalized name: Cal-Quick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: highly viscous glass ionomer with improved mechanical properties than the conventional GI
Trial: NCT05948072
Drug: mFOLFOX 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT05032066
Drug: HZN-825
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Trial: NCT05032066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks.
Trial: NCT06050915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered as a single dose IV infusion or subcutaneous injection
Trial: NCT06050915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
Trial: NCT05627154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A lactose-based tablet.
Trial: NCT05276401
Drug: 5% Bisphosphocin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT05276401
Drug: Placebo Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT05276401
Drug: 10% Bisphosphocin Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT05963217
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
Trial: NCT06596876
Drug: HRG2010; Sustained-release Carbidopa/Levodopa administered placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
Trial: NCT06596876
Drug: Sustained-release Carbidopa/Levodopa; HRG2010 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
Trial: NCT04705584
Drug: Prednisolone (as Acetate)
RxNorm normalized name: prednisolone (as acetate)
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
Trial: NCT06022588
Drug: U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
Trial: NCT06072170
Drug: Kratom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration thirty minutes after the start of a high-fat breakfast
Trial: NCT06072170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration thirty minutes after the start of a high-fat breakfast
Trial: NCT04582916
Drug: 11CPS13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IV followed by PET scanning
Trial: NCT06249113
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% continous intravenous on tumor craniotomy surgery